Download PDF
Arzneimittelforschung 2009; 59(10): 513-520
DOI: 10.1055/s-0031-1296435
Sex Hormones and Inhibitors
Editio Cantor Verlag Aulendorf (Germany)

Study on the Pharmacokinetics of Synthetic Genistein after Multiple Oral Intake in Post-menopausal Women

Jürgen E. Metzner
1   GALMED GmbH, Gesellschaft für galenische und medizinische Forschung, Halle/Saale, (Germany)
,
Thomas Frank
2   Private Consultant, Bad Soden, (Germany)
,
Iris Kunz
3   DSM Nutritional Products Ltd., Basel, (Switzerland)
,
Dominik Burger
3   DSM Nutritional Products Ltd., Basel, (Switzerland)
,
Christoph Riegger
3   DSM Nutritional Products Ltd., Basel, (Switzerland)
› Author Affiliations
Further Information

Publication History

Publication Date:
13 December 2011 (online)

    Permissions and Reprints

Abstract

Genistein (CAS 446-72-0), an isoflavone and phytoestrogen predominantly found in soy, is considered a promising natural bioactive to prevent post-menopausal bone loss.

geniVida™ (previously Bonistein®), a novel product containing of min. 98.5% synthetic genistein aglycone, was investigated in 12 healthy post-menopausal women to assess the safety and tolerabil-ity as well as to obtain pharmacokinetic data after 7 days of repeated intakes. 24 h pharmacokinetic profiles were determined after the first oral dose and after 7 days repeated intakes of 30 mg of the test formulation. Plasma genistein (aglycone) and its conjugates were determined by a standardised LC/MS analytical method using D4-genistein as the internal standard.

The plasma-concentration time profiles for conjugated genistein showed a fast, monophasic one-peak course until Tmax (5.9 h (first dose), 5.3 h (steady state (SS)); Cmax (456.8 ng/ml (first dose), 498.5 ng/ml (SS)). Elimination half-lives (t1/2) were calculated to be 10.8 h (first dose) and 8.2 h (SS), respectively. Determination of AUC(0–inf.) (first dose) was good with a low percentage of extrapolation (3 949.1 h ng/ml). AUC(0–24h) at SS was 5 923.3 h ng/ml. Steady state was reached after 4 to 5 days and no relevant accumulation occurred (R = 1.02).

The test formulation was safe and very well tolerated.

Key words

Bonistein® - CAS 446-72-0 - geniVida™ - Isoflavone - Pharmacokinetics - Phytoestrogen - Safety - Soy
 

  • References

  • 1 Branca F, Lorenzetti S. Health Effects of Phytoestrogens. In: Elmadfa I. editor Diet Diversification and Health Promotion. Forum Nutr. Basel: Karger; 2005. p. 100-111
    CrossrefGoogle Scholar
  • 2 Cassidy A, Albertazzi P, Nielsen IL, Hall W, Williamson G, Tetens I et al. Critical review of health effects of soyabean phyto-oestrogens in post-menopausal women. Proc Nutr Soc. 2006; 65: 76-92
    CrossrefPubMedGoogle Scholar
  • 3 Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M et al. Effects of the Phytoestrogen Genistein on Bone Metabolism in Osteopenic Postmenopausal Women. Ann Internal Med. 2007; 146: 839-48
    PubMedGoogle Scholar
  • 4 Marini H, Bitto A, Altavilla D, Burnett BP, Polito F, Di Stefano V et al. Breast safety and efficacy of genistein aglycone for post-menopausal bone loss: a follow-up study. J Clin Endocrin Metab. 2009; 93: 4787-96
    PubMedGoogle Scholar
  • 5 D’Anna R, Cannata ML, Marini H, Atteritano M, Cancellieri F, Corrado F et al. Effects of the phytoestrogen genistein on hot flushes, edometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study. Menopause. 2009; 16: 1-6
    CrossrefPubMedGoogle Scholar
  • 6 Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J et al. Nonhormonal Therapies for menopausal hot flashes. JAMA. 2006; 295 (17) 2057-71
    CrossrefPubMedGoogle Scholar
  • 7 Messina M, Nagata C, Wu AH. Estimated Asian Adult Soy Protein and Isoflavone Intakes. Nutr Cancer. 2006; 55 (1) 1-12
    CrossrefPubMedGoogle Scholar
  • 8 Setchell KDR, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT et al. Bioavailability of Pure Isoflavones in Healthy Humans and Analysis of Commercial Soy Isoflavone Supplements. J Nutr. 2001; 131: S1362-75
    PubMedGoogle Scholar
  • 9 Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 2005; 81: S230-S42
    PubMedGoogle Scholar
  • 10 McClain RM, Wolz E, Davidovich A, Pfannkuch F, Bausch J. Subchronic and chronic safety studies with genistein in dogs. Food Chem Tox. 2005; 43: 1461-82
    CrossrefPubMedGoogle Scholar
  • 11 McClain RM, Wolz E, Davidovich A, Pfannkuch F, Edwards JA, Bausch J. Acute, subchronic and chronic safety studies with genistein in rats. Food Chem Tox. 2006; 44: 56-80
    CrossrefPubMedGoogle Scholar
  • 12 Ullmann U, Oberwittle H, Grossmann M, Riegger C. Repeated Oral Once Daily Intake of Increasing Doses of the Novel Synthetic Genistein Product Bonistein™ in Healthy Volunteers. Planta Med. 2005; 71: 1-6
    PubMedGoogle Scholar
  • 13 Ullmann U, Metzner J, Frank T, Cohn W, Riegger C. Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Synthetic Genistein (Bonistein™) in Healthy Volunteers. Adv Ther. 2005; 22: 65-78
    CrossrefPubMedGoogle Scholar
  • 14 Pharmacokinetic and statistical assessment related to study GEN/PMW-01.04. Internal report. Halle/Saale (Germany): GALMED GmbH; 2004
    Google Scholar